15+ New Productsjust added, more coming this week

Tesamorlin premium product

Secretagogue Peptide

Tesamorlin

EGRIFTATH9507

A 44-amino acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical studies. Premium Direct-Supply Peptide.

MassChoose an option

Quantity

1

From$149

Contact to Purchase

Fast, protected deliveryTracked USA shipping with discreet packaging.

Tracked USA delivery

Free shipment protection

Priority shipping available

Verified Test Results

Every batch, independently verified.

Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory. The report below reflects the identity, purity and full-panel specification data reported by the lab.

ILSILS LaboratoriesCertificate of Analysis≥99%Purity by HPLC

ISO 17025 Accredited8× Tested

ParameterResultMethodSpecification

Peptide Purity (HPLC)99.61%HPLC>= 95%

Net Peptide Content10.56mgHPLCReport

Identity (HPLC)ConfirmedHPLCMeets spec

AppearanceGoodVisualMeets spec

Fentanyl ScreenNot DetectedImmunoassayPass

Heavy Metals (ICP-MS)Not DetectedICP-MSPass

Sterility (PCR)No GrowthPCRPass

Endotoxin (USP <85>)< 0.05 EU/mLUSP <85>Reported

Third-Party Verified

Certificate of Analysis

Every lot is HPLC-tested at an ISO/IEC 17025-accredited lab. Open any batch's certificate below.

COA information

Tesamorelin 10mg

Latest

LOT TES0003

99.61%HPLC purity · meets spec

Labeled: 10mg
Measured: 10.56mg
Identity: Confirmed
Heavy metals: Not Detected
Sterility: No Growth
Endotoxin: < 0.05 EU/mL
Tested: Jul 30, 2026

8 assays passed · ISO/IEC 17025 accredited

Tesamorelin 10mg

Selected quantity

LOT TES0002

99.61%HPLC purity · meets spec

Labeled: 10mg
Measured: 10.38mg
Identity: Tesamorelin
Heavy metals: Not Detected
Sterility: No Growth
Endotoxin: < 0.05 EU/mL
Tested: Jun 10, 2026

8 assays passed · ISO/IEC 17025 accredited

Tesamorelin 10mg

Selected quantity

LOT TES0001

98.82%HPLC purity · meets spec

Labeled: 10mg
Measured: 10.54mg
Identity: Tesamorelin
Heavy metals: Not Detected
Sterility: No Growth
Endotoxin: < 0.05 EU/mL
Tested: May 29, 2026

7 assays passed · ISO/IEC 17025 accredited

Product Guides & References

Verified publications and source documentation

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of tesamorlin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials

2010PMID: 20554713Falutz J, et al.

View Source LANCET HIV

Effects of tesamorlin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

2019PMID: 31611038Stanley TL, et al.

View Source ARCHIVES OF NEUROLOGY

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults

2012PMID: 22869065Baker LD, et al.

View Source JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Growth Hormone Releasing Hormone Analogue, Tesamorlin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

2019PMID: 31050749Adrian S, et al.

View Source JCI INSIGHT

Effects of tesamorlin on hepatic transcriptomic signatures in HIV-associated NAFLD

2020PMID: 32780726Fourman LT, et al.

View Source FDA

EGRIFTA (tesamorlin) Prescribing Information

2025Theratechnologies Inc.

View Source

DSIP peptide vial

NAD+ peptide vial

All the premium peptides you need, with documented quality and direct-supply support at your fingertips.